Interaction between HT and GP1BA–5T>C and HT and GP6 13254T>C genotypes for CHD
| . | Rx . | n . | Year 1 . | End of follow-up . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases, n . | Rate* . | HR (CI)† . | P‡ . | Cases, n . | Rate* . | HR (CI)† . | P‡ . | |||
| GP1BA | < .001 | < .001 | ||||||||
| TT | P | 789 | 32 | 41.3 | 1.62 (1.03-2.55) | — | 186 | 40.37 | 1.16 (0.95-1.41) | — |
| TT | HT | 790 | 49 | 64.23 | — | — | 211 | 46.55 | — | — |
| TC/CC | P | 258 | 17 | 68.2 | 0.458 (0.2-1.07) | — | 80 | 55.89 | 0.54 (0.38-0.78) | — |
| TC/CC | HT | 253 | 9 | 36.2 | — | — | 49 | 31.8 | — | — |
| GP6 | < .001 | < .001 | ||||||||
| TT | P | 725 | 38 | 53.8 | 0.88 (0.56-1.41) | — | 193 | 46.47 | 0.84 (0.68-1.03) | — |
| TT | HT | 762 | 35 | 47.3 | — | — | 176 | 39.3 | — | — |
| TC/CC | P | 322 | 11 | 34.7 | 2.76 (1.31-5.84) | — | 73 | 38.7 | 1.35 (0.98-1.85) | — |
| TC/CC | HT | 281 | 23 | 84.8 | — | — | 84 | 52.66 | — | — |
| . | Rx . | n . | Year 1 . | End of follow-up . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases, n . | Rate* . | HR (CI)† . | P‡ . | Cases, n . | Rate* . | HR (CI)† . | P‡ . | |||
| GP1BA | < .001 | < .001 | ||||||||
| TT | P | 789 | 32 | 41.3 | 1.62 (1.03-2.55) | — | 186 | 40.37 | 1.16 (0.95-1.41) | — |
| TT | HT | 790 | 49 | 64.23 | — | — | 211 | 46.55 | — | — |
| TC/CC | P | 258 | 17 | 68.2 | 0.458 (0.2-1.07) | — | 80 | 55.89 | 0.54 (0.38-0.78) | — |
| TC/CC | HT | 253 | 9 | 36.2 | — | — | 49 | 31.8 | — | — |
| GP6 | < .001 | < .001 | ||||||||
| TT | P | 725 | 38 | 53.8 | 0.88 (0.56-1.41) | — | 193 | 46.47 | 0.84 (0.68-1.03) | — |
| TT | HT | 762 | 35 | 47.3 | — | — | 176 | 39.3 | — | — |
| TC/CC | P | 322 | 11 | 34.7 | 2.76 (1.31-5.84) | — | 73 | 38.7 | 1.35 (0.98-1.85) | — |
| TC/CC | HT | 281 | 23 | 84.8 | — | — | 84 | 52.66 | — | — |
Rx indicates treatment with placebo (P) or hormone therapy (HT); —, not applicable.
Expressed as n/1000/y.
Hazard ratios and confidence interval for effect of HT after adjustment for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, and aspirin and statin use at baseline.
P value for HT*genotype interaction after adjustment for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, and aspirin and statin use at baseline.